BMO Capital analyst Etzer Darout raised the firm’s price target on Acrivon Therapeutics to $28 from $25 and keeps an Outperform rating on the shares. The firm is updating its model after the company provided a positive update for ACR-368 in patients with high-grade endometrial cancer, achieving a 62.5% overall response rate in patients predicted as responders using the company’s OncoSignature platform, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics: Promising Trial Results and FDA Clearance
- Acrivon Therapeutics upgraded to Buy on cancer data at Ladenburg
- Acrivon Therapeutics upgraded to Buy from Neutral at Ladenburg
- Acrivon reports data from ongoing ACR-368 registrational intent Phase 2 study
- Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis